Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(8 sites)
United States
Stanford University, Palo Alto, California Colorado Blood Cancer Institute, Denver, Colorado University of Chicago, Chicago, Illinois Mayo Clinic - Rochester, Rochester, Minnesota Memorial Sloan Kettering Cancer Center, New York, New York Montefiore Einstein Comprehensive Cancer Center, The Bronx, New York Sarah Cannon Research Insitute, Nashville, Tennessee MD Anderson Cancer Center, Houston, Texas